Falagas M E, Matthaiou D K, Bliziotis I A
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Aliment Pharmacol Ther. 2007 Jan 15;25(2):123-31. doi: 10.1111/j.1365-2036.2006.03154.x.
Intra-abdominal infections result in substantial morbidity and mortality. Fluoroquinolones are among the various regimens that are used for the treatment of these infections.
To evaluate the available data from laboratory and clinical studies regarding the use of fluoroquinolones for the treatment of patients with intra-abdominal infections.
We searched for relevant laboratory and clinical studies in the PubMed and the Cochrane Library databases.
Good pharmacokinetic and pharmacodynamic properties of fluoroquinolones in inflamed abdominal tissue are reported in several laboratory studies. In six prospective non-randomized clinical studies of patients with intra-abdominal infections, the clinical success achieved with the use of fluoroquinolones ranged from 77% to 94%. In 10 randomized-controlled trials fluoroquinolone-based regimens were compared with other commonly used (mainly beta-lactam-based) regimens. Clinical success, bacterial eradication, withdrawal because of toxicity and mortality were similar between the compared treatment arms except from two randomized-controlled trials, in which clinical success was statistically higher in the fluoroquinolone treatment arm.
Fluoroquinolones seem to be an effective and relatively safe option for the treatment of patients with intra-abdominal infections.
腹腔内感染会导致较高的发病率和死亡率。氟喹诺酮类药物是用于治疗这些感染的多种治疗方案之一。
评估有关氟喹诺酮类药物用于治疗腹腔内感染患者的实验室和临床研究的现有数据。
我们在PubMed和Cochrane图书馆数据库中搜索了相关的实验室和临床研究。
多项实验室研究报告了氟喹诺酮类药物在发炎的腹部组织中具有良好的药代动力学和药效学特性。在六项针对腹腔内感染患者的前瞻性非随机临床研究中,使用氟喹诺酮类药物取得的临床成功率在77%至94%之间。在10项随机对照试验中,将基于氟喹诺酮类药物的治疗方案与其他常用(主要是基于β-内酰胺类)治疗方案进行了比较。除两项随机对照试验外,比较的治疗组之间的临床成功率、细菌清除率、因毒性而停药率和死亡率相似,在这两项试验中,氟喹诺酮治疗组的临床成功率在统计学上更高。
氟喹诺酮类药物似乎是治疗腹腔内感染患者的一种有效且相对安全的选择。